CASC3 and mantle cell lymphoma: Multiple combinations of BTZ and cytotoxic chemotherapy, immunomodulatory drug and/or histone deacetylase inhibitors have been intensively investigated in clinical trials to get higher response and better tolerability [6,7,8], implying that BTZ would remain one of the core drugs in treatment regimens and that understanding BTZ resistance is necessary for the long-term management of MCL patients and new therapeutic strategies.